Background
Gilead Sciences develops and sells prescription drugs, including the HIV medication Biktarvy, in domestic and foreign markets. After a Maryland patient received Turkish-market Biktarvy through his employer’s self-funded health plan, Gilead investigated and found that RX Valet, Advanced Pharmacy, Affordable RX Meds, and Gregory Santulli had arranged for hundreds of bottles of foreign-market Gilead medications to be shipped to patients in the United States.
Gilead sued those defendants for direct trademark infringement and alleged that third-party administrator Meritain Health and pharmacy benefit manager ProAct contributorily infringed by supplying services that facilitated the importation scheme. The district court entered a preliminary injunction barring the defendants from advertising, selling, importing, or facilitating the importation of Gilead-branded medications from abroad. The defendants brought four consolidated interlocutory appeals.
The Court’s Holding
The Fourth Circuit affirmed. It held that Gilead was likely to succeed in showing that the imported medications were not genuine goods for Lanham Act purposes, even though Gilead had authorized their manufacture and they were chemically identical to the domestic versions. The foreign products materially differed in labeling, warnings, identifying information, and patient materials, and they reached consumers outside Gilead’s domestic temperature-monitoring, traceability, recall, and secure-distribution controls. Those differences supported a likelihood of consumer confusion and prevented application of the first-sale doctrine.
The court also held that Gilead was likely to establish contributory infringement by Meritain and ProAct. In the Fourth Circuit, a service provider may be liable when it continues supplying services to identified direct infringers whom it knows or has reason to know are infringing; prior specific notice from the trademark owner and a separate showing of control over the means of infringement are not required. The record supported findings that Meritain and ProAct knew or had reason to know both that they were facilitating international sourcing of Gilead drugs and that the imported products differed from domestic versions.
The FDCA’s exclusive-enforcement provision did not preclude the claims because Gilead’s trademark theory depended on material product differences, not proof of an FDCA violation. The court also upheld the findings on irreparable harm, the balance of equities, and the public interest, and declined to exercise pendent appellate jurisdiction over the denial of Santulli’s personal-jurisdiction motion.
Key Takeaways
- Authentic gray-market goods may still be non-genuine under the Lanham Act when they materially differ from authorized domestic products or bypass the trademark owner’s legitimate quality controls.
- For prescription drugs, foreign-language labeling, omitted warnings and identifiers, different patient materials, and exclusion from domestic monitoring, traceability, and recall systems can be material differences.
- Contributory trademark liability may arise when a service provider continues assisting identified infringers despite actual or constructive knowledge; prior notice from the trademark owner and a separate control element are not required in the Fourth Circuit.
Why It Matters
The decision applies the material-differences and quality-control doctrines to foreign-market prescription drugs, making clear that chemical identity alone does not render an imported medicine genuine for trademark purposes. Packaging, safety information, distribution safeguards, and recall access may independently affect the analysis.
The ruling also clarifies the Fourth Circuit’s contributory-infringement standard for intermediaries. Third-party administrators, pharmacy benefit managers, and other service providers may face liability when their data, referral, claims-processing, or payment services facilitate known infringement, even without a cease-and-desist letter or formal control over the direct infringer.